GT200200038A - Conjugados peg de hgf-nk4 - Google Patents

Conjugados peg de hgf-nk4

Info

Publication number
GT200200038A
GT200200038A GT200200038A GT200200038A GT200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A GT 200200038 A GT200200038 A GT 200200038A
Authority
GT
Guatemala
Prior art keywords
hgf
conjugates
peg conjugates
peg
hepatocits
Prior art date
Application number
GT200200038A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200038A publication Critical patent/GT200200038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A CONJUGADOS DEL FRAGMENTO TERMINAL, QUE CONTIENE CUATRO DOMINIOS "KRINGLE", DEL FACTOR DE CRECIMIENTO DE LOS HEPATOCITOS (NK4), CON POLIETILENGLICOL (PEG) DE FORMULA (I) EN DONDE P, X, M, R, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. LOS CONJUGADOS SON DE PROPIEDADES PERFECCIONADAS Y DE UTILIDAD EN TUMORES.
GT200200038A 2001-02-23 2002-02-22 Conjugados peg de hgf-nk4 GT200200038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4

Publications (1)

Publication Number Publication Date
GT200200038A true GT200200038A (es) 2002-09-30

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200038A GT200200038A (es) 2001-02-23 2002-02-22 Conjugados peg de hgf-nk4

Country Status (27)

Country Link
US (2) US20030012775A1 (es)
EP (2) EP1234583A1 (es)
JP (2) JP2004521139A (es)
KR (2) KR20030072629A (es)
CN (1) CN100339393C (es)
AR (1) AR032574A1 (es)
AU (1) AU2002233354B2 (es)
BG (1) BG108125A (es)
BR (1) BR0207510A (es)
CA (1) CA2438308A1 (es)
CZ (1) CZ20032511A3 (es)
EC (1) ECSP034741A (es)
GT (1) GT200200038A (es)
HR (1) HRP20030659A2 (es)
HU (1) HUP0400979A2 (es)
IL (1) IL157426A0 (es)
MA (1) MA26998A1 (es)
MX (1) MXPA03007130A (es)
NO (1) NO20033737L (es)
PA (1) PA8540501A1 (es)
PE (1) PE20020992A1 (es)
PL (1) PL367402A1 (es)
RU (1) RU2293574C2 (es)
SK (1) SK11652003A3 (es)
WO (1) WO2002074344A2 (es)
YU (1) YU65103A (es)
ZA (1) ZA200306080B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
EP1608680A2 (en) * 2003-03-24 2005-12-28 Novo Nordisk A/S Glp-2 derivatives
ES2297673T3 (es) * 2004-03-03 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos.
EP1723236A1 (en) 2004-03-03 2006-11-22 F.Hoffmann-La Roche Ag Method for the recombinant expression of an n-terminal fragment of hepatocyte growth factor
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CN102046792B (zh) * 2008-04-09 2014-12-10 百疗医株式会社 用于提高质粒dna表达的冻干dna制剂
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3919128A4 (en) * 2019-01-28 2023-01-11 Toray Industries, Inc. POLYETHYLENE GLYCOL MODIFIED BODY FOR HEPATORYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF
CN113382775A (zh) * 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0642580T3 (da) 1992-05-18 2002-12-23 Genentech Inc Hepactocytvækstfaktorvarianter
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
EE9600121A (et) * 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
DE69936409T2 (de) * 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU3323002A (en) * 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates

Also Published As

Publication number Publication date
PL367402A1 (en) 2005-02-21
KR20030072629A (ko) 2003-09-15
JP2010174034A (ja) 2010-08-12
CZ20032511A3 (en) 2004-03-17
EP1389132A2 (en) 2004-02-18
HUP0400979A2 (hu) 2004-08-30
MA26998A1 (fr) 2004-12-20
MXPA03007130A (es) 2003-11-18
HRP20030659A2 (en) 2004-08-31
IL157426A0 (en) 2004-03-28
ECSP034741A (es) 2003-10-28
BR0207510A (pt) 2004-07-27
US20030012775A1 (en) 2003-01-16
YU65103A (sh) 2006-03-03
AR032574A1 (es) 2003-11-12
US20080085857A1 (en) 2008-04-10
NO20033737D0 (no) 2003-08-22
RU2293574C2 (ru) 2007-02-20
CN1571679A (zh) 2005-01-26
PE20020992A1 (es) 2002-11-01
CA2438308A1 (en) 2002-09-26
RU2003127395A (ru) 2005-03-20
EP1234583A1 (en) 2002-08-28
KR20090020713A (ko) 2009-02-26
US7846896B2 (en) 2010-12-07
ZA200306080B (en) 2004-11-23
CN100339393C (zh) 2007-09-26
JP2004521139A (ja) 2004-07-15
AU2002233354B2 (en) 2006-11-30
WO2002074344A3 (en) 2003-12-04
BG108125A (bg) 2004-09-30
SK11652003A3 (sk) 2004-05-04
PA8540501A1 (es) 2002-09-30
NO20033737L (no) 2003-10-21
WO2002074344A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
ATE246202T1 (de) Gcsf konjugate
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
CY1117027T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
FI103410B1 (fi) Starburst-konjugaatteja
DE60024581D1 (de) 6-phenylphenanthridine mit pde-iv hemmender wirkung
DK1568772T3 (da) Varianter af humant væksthormon
DE60122335D1 (de) Zusammensetzung auf der basis polymerer mizellen
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
BR0208741A (pt) Derivados de piperidina
AR027355A1 (es) Acidos tiazolidincarboxilicos
ATE290784T1 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
SE0004245D0 (sv) Novel compounds and their use
AR032574A1 (es) Conjugados peg de hgf-nk4
SE0003476D0 (sv) Compounds
DE60025327D1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
BR0010981A (pt) Benzopiranos anelados em c7-c8 com um heterociclo aromático e composições e matrizes
PT1204659E (pt) Benzofuranos serotoninergicos
BRPI0415285A (pt) derivados de aminoalcanol
DE60315288D1 (de) Cyanoguanidin prodrugs
BR9814188A (pt) "agonistas de 5-ht1f"
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
ATE313587T1 (de) S-b-s zusammensetzungen
UY26498A1 (es) Pirroles sustituidos